TLSI 8-K: Press release on business update and quarter ended Sept 30, 2025

Rhea-AI Filing Summary

TriSalus Life Sciences (TLSI) furnished a press release providing a business update and financial results for the quarter ended September 30, 2025.

The release is attached as Exhibit 99.1 and, along with the Inline XBRL cover file (Exhibit 104), is furnished and not deemed filed under Section 18, and is incorporated by reference only if specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

0001826667FALSE00018266672025-11-132025-11-130001826667us-gaap:CommonStockMember2025-11-132025-11-130001826667us-gaap:WarrantMember2025-11-132025-11-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2025

TRISALUS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-39813			85-3009869
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(I.R.S. Employer Identification No.)
6272 W 91st Ave, Westminster, Colorado						80031
(Address of principal executive office)						(Zip Code)

(888) 321-5212

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $0.0001 par value			TLSI			Nasdaq Global Market
Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share			TLSIW			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Conditions.

On November 13, 2025, TriSalus Life Sciences, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter ended September 30, 2025. A copy of the press is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

This information, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and it will not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.

Item 9.01						Financial Statements and Exhibits.
(d)
Exhibit Number						Description
99.1						Press Release dated November 13, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 13, 2025			TriSalus Life Sciences, Inc.
			By:			/s/ David Patience
						Name:			David Patience
						Title:			Chief Financial Officer

FAQ

What did TLSI announce in its 8-K?

TriSalus Life Sciences furnished a press release with a business update and financial results for the quarter ended September 30, 2025.

Which exhibits were included with TLSI's 8-K filing?

Exhibit 99.1 (press release dated November 13, 2025) and Exhibit 104 (Inline XBRL cover page).

How is the press release treated for liability purposes?

It is furnished, not deemed filed under Section 18, and only incorporated by reference if specifically referenced.

What period do the results cover for TLSI?

The results cover the quarter ended September 30, 2025.

What are TLSI's trading symbols and where are they listed?

Common stock: TLSI on Nasdaq Global Market; Warrants: TLSIW on Nasdaq Global Market.

What is the exercise price of TLSI’s listed warrants?

Each whole warrant is exercisable for one common share at $11.50 per share.

Is TriSalus Life Sciences an emerging growth company?

Yes, the company is marked as an emerging growth company.